4VANE J R.My life and times with enzymes and mediators[J].Med Sci Monit,2001,7 (4):790 -800.
5BOMBARDIET C,LAINE L,REICIN A,et al.Comparisom of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis:VIGOR Study Group[J].N Engl J Med,2000,343(21):1520-1528.
6[1]Lichtenstein D, Syngal S, Wlfe MM. Non-steroidal antiinflammatory drugs and the gastrointestinal tract. Arthritis Rherm,1995;38:1:5～18.
7[2]Bjarnason I, Macpherson A, Somasundaram S, et al. Lower bowel toxicity of non-steroidal anti-inflammatory drugs. Lewis A: Non-steroidal Anti-Inflammatory Drugs, Mechanisms and Clinical Uses. New York: NY, Marcel Dekker, 1994;145～157.
8[3]Marie R, Griffin, MD. Epidemiology of non-steroidal antiinflammatory drug-associated gastrointestinal injury. Am J Med.1998;104: 23～28.
9[4]Fujiwara Y, Schmassman A, Arakawa T, et al. Indomethacin interferes with epidermal growth factor binding and proliferative response of KATO Ⅲ cells. Digestion, 1995;56:364～369.
10[5]Henry D, Robertson J. Non-steroidal anti-inflammatory drugs and peptic ulcer hospitalization rates in New South Wales.Gastroenterology. 1993; 104:1083～ 1091.
